Insulin sensitizers in adolescents with polycystic ovary syndrome
| Autor: | Wickham Ep rd, Le Tn, Nestler Je |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
medicine.medical_specialty Adolescent endocrine system diseases medicine.medical_treatment Physiology Contraceptives Oral Hormonal 03 medical and health sciences 0302 clinical medicine Insulin resistance Weight loss 030225 pediatrics Internal medicine Weight Loss medicine Humans Hypoglycemic Agents 030212 general & internal medicine Acne business.industry Insulin Age Factors medicine.disease Polycystic ovary Metformin female genital diseases and pregnancy complications Endocrinology Hormonal contraception Pediatrics Perinatology and Child Health Female Thiazolidinediones Insulin Resistance medicine.symptom business Inositol Polycystic Ovary Syndrome Hormone medicine.drug |
| Zdroj: | Minerva Pediatrics. 69 |
| ISSN: | 2724-5780 2724-5276 |
| Popis: | Polycystic ovary syndrome (PCOS) is the most common disorder of androgen excess in women of reproductive age. The diagnosis of PCOS can be more challenging in adolescents than in adult women given significant overlap between normal puberty and the signs of PCOS, including acne, menstrual irregularity, and polycystic ovarian morphology. Optimal treatments for adult women with PCOS vary depending on patient risk factors and reproductive goals, but mainly include hormonal contraception and insulin sensitizers. There is continued interest in targeting the intrinsic insulin resistance that contributes to metabolic and hormonal derangements associated with PCOS. The vast majority of published data on insulin sensitizing PCOS treatments are reported in adult women; these have included weight loss, metformin, thiazolidinediones, and the inositols. Furthermore, there is also a small but growing body of evidence in support of the use of insulin sensitizers in adolescents, with or without oral contraceptives. Discussion of the available treatments, including benefits, potential side effects, and incorporation of patient and family preferences is critical in developing a plan of care aimed at achieving patient-important improvements in PCOS signs and symptoms while addressing the longer-term cardiometabolic risks associated with the syndrome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|